M032

M032 is a second-generation oncolytic herpes simplex virus (oHSV) that is conditionally replication competent. It selectively replicates in tumor cells, leading to direct oncolysis and the release of new viral particles that can infect neighboring tumor cells. In addition to its direct cytolytic effect, M032 has been engineered to express interleukin-12 (IL-12), which stimulates an immune response against residual tumor cells and exerts anti-angiogenic effects by inhibiting the formation of new blood vessels necessary for tumor growth. The therapy aims to combine direct viral-mediated cell killing with immune activation and anti-angiogenesis for enhanced antitumor efficacy. Developed at the University of Alabama at Birmingham, it is being investigated primarily as a gene therapy for cancer[5].

Other names

M032M-032M 032